The B-cell receptor (BCR) signaling pathway is involved in the development of many B-cell malignancies, which makes it one of the targets for inhibitors in B-cell non-Hodgkin Lymphoma (NHL). Here, BCR is linked to B-cell non-Hodgkin lymphoma.